ATP assays market to reach $3.88 billion by 2030

The adenosine triphosphate (ATP) assays market is projected to grow at a 12.2% CAGR to $3.88 billion by 2030, according to a new Business Research Company report. Rising cancer, chronic disease and infectious disease rates, plus demand for personalized medicine and automated testing, are driving the market.

Why it matters: - ATP assays are used to measure cellular energy and viability, making them important in research, diagnostics and drug development. - Demand is rising as health systems, biotech firms and labs need faster ways to assess treatment response, contamination and disease activity. - The market outlook points to continued growth in tools used across clinical diagnostics, personalized medicine, food safety and environmental monitoring.

What happened: - The Business Research Company released The Adenosine Triphosphate (ATP) Assays Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the ATP assays market grew from $2.19 billion in 2025 to $2.45 billion in 2026. - The report projects the market will reach $3.88 billion by 2030, implying a 12.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Historical growth was supported by limited availability of high-sensitivity ATP assay kits, reliance on traditional biochemical assay methods, more pharmaceutical research, wider use of molecular biology techniques, and stronger focus on food safety and environmental monitoring. - Forecast growth is tied to high-throughput ATP assay platforms, greater integration with automated lab instruments, broader use in clinical diagnostics and personalized medicine, more biotech research and drug development, and improvements in fluorescent and luminescent assays. - Emerging trends include expanded use in drug discovery, cell-based viability and cytotoxicity testing, food safety checks, environmental evaluations, luminometric and enzymatic ATP assays, and efforts to improve assay sensitivity, accuracy and standardization. - Rising cancer, chronic illness and infectious disease rates are a key demand driver because ATP assays can help assess cellular viability, detect microbial contamination, measure treatment effectiveness and monitor metabolic and mitochondrial dysfunction. - The World Health Organization projected in February 2024 that new cancer cases will exceed 35 million by 2050, up 77% from 20 million in 2022. - The European Centre for Disease Prevention and Control reported in November 2024 that 112,883 HIV diagnoses were recorded in 2023 across 47 countries, including 24,731 in the EU/EEA. - The crude HIV diagnosis rate rose to 12.7 per 100,000 people, up 2.4% from 12.4 per 100,000 in 2022. - Personalized medicine is also supporting demand because ATP assays help test antimicrobial efficacy against specific pathogens and guide more individualized therapies. - The Personalized Medicine Coalition said the US Food and Drug Administration approved 12 personalized medicines in 2022, equal to about 34% of all newly approved therapeutic molecular entities. - The report says 2026 market coverage now includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated future-trend analysis.

Between the lines: - The report points to a market shifting from basic assay use toward more automated, standardized and higher-throughput workflows. - Stronger demand from disease testing and personalized medicine suggests ATP assays are becoming more embedded in routine development and monitoring decisions, not just research settings. - Regional leadership in North America and faster growth in Asia-Pacific suggest established demand in mature markets and expansion tied to biotech investment and healthcare access elsewhere.

What's next: - The market is expected to keep expanding as laboratories adopt more automated platforms and more sensitive assay formats. - Growth will likely track broader trends in drug discovery, clinical diagnostics, and personalized treatment selection. - More information and the full report are available from The Business Research Company.